Evidence map›Paper›PMID 36750562›Full record

ArticleNature communications2023

Dissecting the immune suppressive human prostate tumor microenvironment via integrated single-cell and spatial transcriptomic analyses.

Taghreed Hirz, Shenglin Mei, Hirak Sarkar, Youmna Kfoury, Shulin Wu, Bronte M Verhoeven, Alexander O Subtelny, Dimitar V Zlatev, Matthew W Wszolek, Keyan Salari and 10 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature communications, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 238 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
238citing papers in PubMed, 1 pooled it
50.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

238 citing papers in PubMed, 1 synthesis or guideline pooled it, 219 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Review
  13. Review
  14. Article
  15. Article
  16. Immune Spatial Organization Predicts Distant Metastasis Risk in Aggressive Localized Prostate Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026
    Article
  17. Molecular Mechanisms and Immune Regulation in Prostate Cancer: A Review.International journal of molecular sciences · 2026
    Review
  18. Review
  19. Article
  20. Review

178 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 3 institutions in 2 countries.

Taghreed Hirz *Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. THIRZ@mgh.harvard.edu.ORCID 0000-0001-9230-1756
Shenglin Mei *Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. smei8@mgh.harvard.edu.ORCID 0000-0001-8258-5898
Hirak SarkarDepartment of Biomedical Informatics, Harvard Medical School, Boston, MA, USA.
Youmna KfouryCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.
Shulin WuDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Bronte M VerhoevenChildhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.
Alexander O SubtelnyDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Dimitar V ZlatevDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Matthew W WszolekDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Keyan SalariDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.ORCID 0000-0001-7940-4558
Evan MurrayBroad Institute of Harvard and MIT, Cambridge, MA, USA.
Fei ChenBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0003-2308-3649
Evan Z MacoskoBroad Institute of Harvard and MIT, Cambridge, MA, USA.ORCID 0000-0002-2794-5165
Chin-Lee WuDepartment of Pathology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
David T ScaddenCenter for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA.
Douglas M DahlDepartment of Urology, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Ninib Baryawno *Childhood Cancer Research Unit, Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6054-4163
Philip J Saylor *Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, MA, USA.ORCID 0000-0003-4849-3695
Peter V Kharchenko *Harvard Stem Cell Institute, Cambridge, MA, USA.ORCID 0000-0002-6036-5875
David B Sykes *Center for Regenerative Medicine, Massachusetts General Hospital, Boston, MA, USA. DBSYKES@mgh.harvard.edu.ORCID 0000-0002-9788-0221
Harvard University · USBroad Institute · USKarolinska Institutet · SE

Funding

VectorP30CA006516 · NCI · DANA-FARBER CANCER INSTITUTE · PI Irene M. Ghobrial · 1985 to 2026
$330.6M
Stromal Regulation of Bone MetastasisU54CA163191 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI KALLURI, RAGHU · 2011 to 2015
$4.8M
Sequence-specific Hybridization Capture to Reveal the lncRNA Interactome in Prostate CancerR01CA193481 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI DAVID F. JARRARD, Lloyd M Smith · 2015 to 2026
$3.4M
Cell and Molecular Dynamics of Hematopoiesis In VivoR24DK103074 · NIDDK · HARVARD UNIVERSITY · PI SCADDEN, DAVID T · 2015 to 2018
$3.0M
Statistical methods for analysis of single-cell variabilityR01HL131768 · NHLBI · HARVARD MEDICAL SCHOOL · PI KHARCHENKO, PETER V · 2015 to 2019
$2.4M
NCI NIH HHS P30 CA006516NCI NIH HHS R01 CA193481NCI NIH HHS U54 CA163191NHLBI NIH HHS R01 HL131768NIDDK NIH HHS R24 DK103074
6 · The paper itself

Abstract

The treatment of low-risk primary prostate cancer entails active surveillance only, while high-risk disease requires multimodal treatment including surgery, radiation therapy, and hormonal therapy. Recurrence and development of metastatic disease remains a clinical problem, without a clear understanding of what drives immune escape and tumor progression. Here, we comprehensively describe the tumor microenvironment of localized prostate cancer in comparison with adjacent normal samples and healthy controls. Single-cell RNA sequencing and high-resolution spatial transcriptomic analyses reveal tumor context dependent changes in gene expression. Our data indicate that an immune suppressive tumor microenvironment associates with suppressive myeloid populations and exhausted T-cells, in addition to high stromal angiogenic activity. We infer cell-to-cell relationships from high throughput ligand-receptor interaction measurements within undissociated tissue sections. Our work thus provides a highly detailed and comprehensive resource of the prostate tumor microenvironment as well as tumor-stromal cell interactions.

Indexed as

Prostatic NeoplasmsTranscriptomeGene Expression ProfilingHumansMaleProstateTumor Microenvironment

Identifiers

PMID36750562
PMCPMC9905093
OpenAlexW4319440743

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.